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Editorial
Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?
Synchronous oligometastatic (sOM) status is perceived as a distinct
disease from polymetastatic presentation, with a potential higher overall
survival (OS) probability when treated with local radical treatment (LRT).
Recently, the long-term outcomes of the practice changing phase II
randomized trial on sOM non-small cell lung cancer (NSCLC) were
published [1]. Forty-nine patients with up to 3 metastases (primary
tumor excluded) after first line systemic therapy were randomized to
either LRT (i.e. radiotherapy or surgery) to all disease sites or
maintenance systemic therapy (MT)/observation (O). This trial de-
monstrated that LRT improved OS, median 41.2 months (95 % CI, 18.9
months to not reached) in LRT and 17.0 months (95 % CI, 10.1–39.8
months) in MT/O (p=0.017). These results supported the integration
of LRT in sOM-NSCLC and its implementation in daily clinical practice.
However, despite some consensus about sOM status, a uniform defini-
tion does not exist as reported in a systematic review performed by the
European Organization for the Research and Treatment of Cancer (EORTC)
Table 1
Article included in the systematic review [2] and current literature [3,4].
Articles Number of
patients
Maximal number
metastases defined
Maximal number of
metastases treated
Patients with ≤ 2 metastases treated
(%)
Patients with ≥ 3 metastases included
(%)
Downey R. 2002 23 1 1 100% 0%
Khan A. 2006 23 2 2 100% 0%
Inoue St et al. 2010 25 5 5 N.A. N.A.
Cheruvu P. 2011 38 8 8 N.A N.A
Collaud S. 2012 29 1 1 100% 0%
Congedo M. 2012 53 2 2 100% 0%
De Ruysscher D. 2012 40 5 3 97.4% 2.6%
Lopez Guerra J. 2012 78 4 4 91% 9%
Griffioen G. 2013 61 3 3 96.7% 3.3%
Nieder C.S. 2014 23 3 2 100% 0%
Parikh R. 2014 186 5 5 74% 26%
Sheu T. 2014 90 3 3 88% 12%
Plones T. 2015 56 5 4 99% 1%
Su Ss. 2015 198 3 3 56%* 44%*
Xanthopoulos E. et al. 2015 25 4 4 84% 16%
Fleckenstein J. 2016 39 5 5 90% 10%
Johnson K. 2016 37 5 N.A. N.A. N.A.
Sakai Ks.2016 18 5 N.A. N.A. N.A.
Su Ss. 2016 91 4 N.A. N.A. N.A.
Iyengar P. 2017 29 5 3 93%** 7%
Gomez D. 2019 49 3 3 98% 2%
Bauml JM.
2019 [3]
51 4 4 94% 6%
Arrieta O.
2019 [4]
37 5 N.A. 65% 35%
*56 % with single metastasis, 44 % ≥ 2 metastases; ** 14 patients received a LCT (randomized trial); N.A.: not available.
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lung cancer group (LCG) [2]. Specifically, EORTC (in collaboration with
European Society for radiotherapy and oncology – ESTRO) is promoting an
ongoing trial (E²-RADIatE–OligoCare) including sOM and oligorecurrent
patients with the primary outcome to identify patient, tumour (NSCLC,
breast, prostate and colon-rectal cancers) staging and treatment character-
istics impacting in OS.
About the systematic review, the aim was to provide an overview of
sOM-NSCLC definition from reported series and trials [2]. The max-
imum number of metastases ranged from 1 to 8 in 21 selected articles
[2]. Additionally, the definition of sOM-NSCLC in prospective clinical
trials is also heterogeneous and vary between 1 and 6 [2–5]. Further,
74–100% of 1211 included in the systematic review patients had ≤2
metastatic sites. Furthermore, total numbers of metastases detected and
treated were not described in 5 (24 %) studies, restricting clinical in-
terpretation on the role of LRT (Table 1). In the recent randomized
Gomez et al. trial, inclusion criteria allowed up to three metastases but
the majority of patients (65 %) had only 0–1 [1].
Not surprisingly, the field is moving towards allowing higher
number of metastases in clinical trials, as technically LRT is feasible for
an increasing number of sites.
Recently, the EORTC-LCG published a consensus about the maximal
number of metastases allowed to define sOM-NSCLC. Authors evaluated
sOM-NSCLC definitions in daily clinical practice in Europe, by a survey
and discussion of ten real life cases [7,8]. In the survey, the maximum
number of metastases considered as sOM-NSCLC was again variable and
42 % of responders identified 3 as the correct definition [7]. Then
analyzing real life cases, sOM-NSCLC was conservative and linked to
radical intent of treatment. Members of the consensus meeting con-
cluded that the maximum number of metastases is depending on the
possibility to offer a LRT strategy [6].
Finally, based on the systematic review, most studies did not specify
the local nodal status (N-status), although it is known that advanced N-
status is associated with lower OS [7]. In the Gomez et al. trial, besides
LRT, only number of metastases and presence of a driver alteration were
associated with improved OS [1]. N2/N3 disease was non-significant in
OS, probably due to the limited number of enrolled patients. As even, in
Gomez et al. not all patients benefited from LRT and a correct selection is
advocated. The ongoing SARON trial (NCT02417662) could provide
answers, as patients will be stratified according to mediastinal N-status
(N 0-1 vs N2-3), histology (adeno- vs non-adenocarcinoma), brain me-
tastases (present vs absent) and number of oligometastatic sites (1 vs 2 vs
3). Other factors such as circulating tumour DNA and molecular sig-
natures should be evaluated in future trials [10,11].
In order to select sOM-NSCLC patients, accurate radiological and
pathological staging (preferably including molecular characterization)
is needed [9]. Therefore, as described in EORTC articles [2,5], 18FDG-
PET-CT, brain MRI-scan and a possible pathological proof of a
metastasis are necessary. The promising data about immunotherapy
and radiation combination are inspiring new sOM-NSCLC trials, in-
vestigating the association of these treatments [3]. Hence, a single
definition and recommended staging work-up are crucial.
The EORTC LCG approach is based on a secure methodology, be-
cause expert team carried out the systematic review, while survey and
clinical cases discussion contributed on basic scenario about sOM-
NSCLC treatment in Europe. Finally, a consensus meeting was held.
Based on findings coming from the previous 3 steps, proposals were
discussed and definitions were consensually agreed between scientific
societies involved in lung cancer treatment (surgeon, pneumologist,
radiation and medical oncologist) [6]. The EORTC LCG consensus de-
finition is a good starting point for future clinical trials selecting the
correct patient for the fit oncological treatment [5].
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